Drugs / Morphine SR
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT01309386 Comparator | Aug 2010 → Jan 2012 | neoplasm | Janssen Pharmaceutical K.K. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Morphine SR | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01309386 ↗ |
| Known as | morphine sustained-release | “randomized (1:1) to receive twice-daily treatment with tapentadol ER (100-500 mg/day) or morphine sustained release (SR; 20-140 mg/day; reference for assay sensitivity).” PMID 24906437 ↗ Jul 2014 |
| Route | Oral | “Morphine SR 30 to 120 mg orally daily for 8 weeks” NCT01309386 ↗ |